Kyowa Kirin Pharmaceutical Research, Inc.

73 articles about Kyowa Kirin Pharmaceutical Research, Inc.

• Syndax Pharmaceuticals Inc. Snags $125 Million Deal With Kyowa Hakko Kirin

  1/8/2015

• Ono Pharmaceutical Company, Ltd., Bristol-Myers Squibb Company, And Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (Nivolumab) And Mogamulizumab In Advanced Solid Tumors

  12/10/2014

• Pfizer, Kyowa Hakko Kirin Team Up On Immuno-Oncology Combination Study

  9/30/2014

• Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study

  9/30/2014

• ArQule, Inc. Announces Commencement Of Phase 3 Clinical Trial With Tivantinib In Hepatocellular Carcinoma By Partner Kyowa Hakko Kirin In Japan

  2/4/2014

• The NovAliX/Kyowa Hakko Kirin Alliance Will Commence A Fragment-Based Drug Discovery Project Targeting An Important Protein/Protein Interaction

  11/18/2013

• Ultragenyx Pharmaceuticals Announces the Presentation of Data From a Single Dose Phase 1 Study, Conducted by Kyowa Hakko Kirin, of KRN23 in X-linked Hypophosphatemia (XLH) in Adults

  10/7/2013

• Abstral® , Manufactured and Packaged by Recipharm AB for Kyowa Hakko Kirin, Has Been Approved in Japan

  9/23/2013

• Activiomics Extends Research Agreement With Kyowa Hakko Kirin as Part of Its Strategic Partnership With BioFocus DPI

  9/19/2013

• Ultragenyx Pharmaceuticals Announces Collaboration With Kyowa Hakko Kirin to Develop and Commercialize Phase 2-Stage KRN23 for X-Linked Hypophosphatemia

  9/4/2013

• La Jolla Institute for Allergy and Immunology Continues Longtime Collaboration With Kyowa Hakko Kirin

  8/1/2013

• Ezose Sciences, Inc. Enters Glycomics Research Agreement With Kyowa Hakko Kirin

  1/28/2013

• NovAliX Enters Into Fragment-Based Drug Discovery Alliance With Kyowa Hakko Kirin

  1/14/2013

• Adimab LLC. Announces New Discovery Collaboration ith Kyowa Hakko Kirin

  1/7/2013

• Dicerna Pharmaceuticals Announces That Kyowa Hakko Kirin Has Selected a Second DsiRNA Therapeutic Candidate for Development, Triggering $5 Million Milestone Payment

  1/3/2013

• Anchor Therapeutics Enters Into Collaborative Research Agreement With Kyowa Hakko Kirin for its Pepducin Technology

  7/31/2012

• Fujifilm Kyowa Kirin Biologics Launches, Joint Venture of FUJIFILM Holdings Corporation and Kyowa Hakko Kirin for the Development, Manufacturing and Sales of Biosimilars

  3/27/2012

• La Jolla Institute for Allergy and Immunology and Kyowa Hakko Kirin Celebrate 5th Anniversary in University of California, San Diego (UCSD)'s Science Research Park

  7/1/2011

• Japanese Company Kyowa Hakko Kirin to Buy ProStrakan Group for £292 Million

  2/22/2011

• Dicerna Pharmaceuticals Expands Pact Kyowa Hakko Kirin; Original Agreement Worth $1.4 Billion Potentially

  12/7/2010